Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 4:21 PM ET

Diversified Consumer Services

Company Overview of University of Southern California

Company Overview

University of Southern California is an educational institution that offers accounting, computer science, civil engineering, advertising, and management programs. The schools of the university include The College of Letters, Arts and Sciences, which offers undergraduate, graduate, and doctoral degrees in over 30 academic departments such as sciences and social sciences, civic and cultural studies, and international and language studies; The Graduate School focuses on academic and professional affairs of the university; and Professional Schools including the Schools of Pharmacy and Medicine. The institution was founded in 1880 and is based in Los Angeles, California.

University Park Campus

Los Angeles, CA 90089

United States

Founded in 1880





Key Executives for University of Southern California

President and Trustee
Age: 62
Chief Financial Officer and Senior Vice President, Finance
Age: 70
Dean of USC College
Vice President of Student Affairs
Senior Vice President of Advancement
Compensation as of Fiscal Year 2015.

University of Southern California Key Developments

University of Southern California Presents at AusBiotech National Conference 2015, Oct-08-2015 09:00 AM

University of Southern California Presents at AusBiotech National Conference 2015, Oct-08-2015 09:00 AM. Venue: Victoria, Australia. Speakers: Dushyant Pathak, Associate Vice Chancellor, Office of Research Technology Management & Corporate Relations.

The University of Southern California Wins $4.69 Million Federal Contract

The University of Southern California won a $4,689,063 federal contract from the Defense Advanced Research Projects Agency, Arlington, Virginia, for R&D on low resource languages for emergent incidents (LORELEI).

Caladrius Biosciences, Inc. Announces Research Collaboration with the University of Southern California and California Institute of Technology

Caladrius Biosciences, Inc. announced that it has entered into a material transfer agreement with the University of Southern California and the California Institute of Technology, concerning next-generation strategies for its core cancer technology. This research collaboration will build on Caladrius' highly successful manufacturing protocol for its lead cancer program, CLBS20 (aka NBS20), by exploring techniques to further enhance the isolation of cancer initiating cells with the goal of increasing the number of cancer patients that might benefit from treatment. CLBS20 is the subject of a Phase 3 clinical trial investigating its efficacy in the treatment of late-stage melanoma, the Intus Study. The trial has been granted a Special Protocol Assessment by the US Food and Drug Administration (FDA) and the CLBS20 development program has been granted Orphan Drug and Fast Track designations by FDA. Randomization of the first patient in the Intus trial occurred in April 2015. Advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are 20,000 estimated new cases, and an estimated 10,000 deaths, from metastatic melanoma each year in the United States. The US melanoma market is approximately $1 billion per year, which is predominantly spent to treat metastatic melanoma. The platform on which CLBS20 is based is potentially applicable across multiple solid tumor types, including lung, colon and ovarian cancer, hepatocellular carcinoma and glioblastoma multiforme. CLBS20 uses the patient's own immune cells and tumor-initiating cells to create an immunotherapy therapeutic vaccine. It is unique in targeting these cancer- or tumor-initiating cells; other therapies, which target different tumor cells, may treat existing cancer but may not be as likely to prevent tumor recurrence.

Similar Private Companies By Industry

Company Name Region
Equitable Homeworks, LLC United States
Tradewinds Heating & Air Conditioning United States
Fast Towing, Inc. United States
SCI Capital II United States
Party Rental Ltd. United States

Recent Private Companies Transactions

August 9, 2015
Response Genetics, Inc

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact University of Southern California, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at